Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Apr;48(4):414-425.
doi: 10.1007/s00134-022-06638-9. Epub 2022 Feb 27.

Prophylactic melatonin for delirium in intensive care (Pro-MEDIC): a randomized controlled trial

Bradley Wibrow  1   2 , F Eduardo Martinez  3   4 , Erina Myers  5   6 , Andrew Chapman  7 , Edward Litton  8   9 , Kwok M Ho  8   7   10 , Adrian Regli  8   11   12 , David Hawkins  13 , Andrew Ford  8   14 , Frank M P van Haren  15   16   17 , Simon Wyer  18 , Joe McCaffrey  19 , Alan Rashid  20 , Erin Kelty  21 , Kevin Murray  21 , Matthew Anstey  5   8   22
Affiliations
Randomized Controlled Trial

Prophylactic melatonin for delirium in intensive care (Pro-MEDIC): a randomized controlled trial

Bradley Wibrow et al. Intensive Care Med. 2022 Apr.

Abstract

Purpose: Delirium is common in the critically ill, highly distressing to patients and families and associated with increased morbidity and mortality. Results of studies on preventative use of melatonin in various patient groups have produced mixed results. The aim of this study was to determine whether administration of melatonin decreases the prevalence of delirium in critically ill patients.

Methods: Multicentre, randomized, placebo-controlled, double-blind trial across 12 Australian ICUs recruiting patients from July 2016 to September 2019. Patients of at least 18 years requiring ICU admission with an expected length of stay (LOS) greater than 72 h; enrolled within 48 h of ICU admission. Indistinguishable liquid melatonin (4 mg; n = 419) or placebo (n = 422) was administered enterally at 21:00 h for 14 consecutive nights or until ICU discharge. The primary outcome was the proportion of delirium-free assessments, as a marker of delirium prevalence, within 14 days or before ICU discharge. Delirium was assessed twice daily using the Confusion Assessment Method for ICU (CAM-ICU) score. Secondary outcomes included sleep quality and quantity, hospital and ICU LOS, and hospital and 90-day mortality.

Results: A total of 847 patients were randomized into the study with 841 included in data analysis. Baseline characteristics of the participants were similar. There was no significant difference in the average proportion of delirium-free assessments per patient between the melatonin and placebo groups (79.2 vs 80% respectively, p = 0.547). There was no significant difference in any secondary outcomes including ICU LOS (median: 5 vs 5 days, p = 0.135), hospital LOS (median: 14 vs 12 days, p = 0816), mortality at any time point including at 90 days (15.5 vs 15.6% p = 0.948), nor in the quantity or quality of sleep. There were no serious adverse events reported in either group.

Conclusion: Enteral melatonin initiated within 48 h of ICU admission did not reduce the prevalence of delirium compared to placebo. These findings do not support the routine early use of melatonin in the critically ill.

Keywords: Delrium; Intensive care; Melatonin; Sleep.

PubMed Disclaimer

Comment in

References

    1. American Psychiatric Association (APA), Washington (2020) Diagnostic and statistical manual of mental disorders, 5th edn. APA
    1. Girard TD, Pandharipande PP, Carson SS et al (2010) Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. Crit Care Med 38(2):428–437. https://doi.org/10.1097/ccm.0b013e3181c58715 - DOI - PubMed - PMC
    1. Devlin JW, Roberts RJ, Fong JJ et al (2010) Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med 38(2):419–427. https://doi.org/10.1097/CCM.0b013e3181b9e302 - DOI - PubMed
    1. Ouimet S, Kavanagh BP, Gottfried SB, Skrobik Y (2007) Incidence, risk factors and consequences of ICU delirium. Intensive Care Med 33(1):66–73. https://doi.org/10.1007/s00134-006-0399-8 - DOI - PubMed
    1. Grover S, Ghosh A, Ghormode D (2014) Experience in delirium: is it distressing? J Neuropsychiatry Clin Neurosci 27(2):139–146. https://doi.org/10.1176/appi.neuropsych.13110329 - DOI - PubMed

Publication types

LinkOut - more resources